Mesoblast

Aktuelle Nachrichten

Schlagzeilen in der Originalsprache der Quelle.

• Mesoblast Limited (ASX:MSB) Builds Ryoncil Revenue Base as FY26 Loss Narrows (öffnet in neuem Tab)

  Kalkine · 01.10.2026

• State Street Group Cuts Mesoblast Stake Below Substantial Holder Threshold (öffnet in neuem Tab)

  TipRanks · 01.10.2026

• Mesoblast Subject to State Street Substantial Holder Cessation Notice (öffnet in neuem Tab)

  Kalkine · 01.10.2026

• Why Are Mesoblast (ASX:MSB) Shares Slipping Despite FDA Approval? (öffnet in neuem Tab)

  Kalkine Media · 01.10.2026

• Mesoblast Limited Subject to New Substantial Holder Notice from State Street Corporation (öffnet in neuem Tab)

  Kalkine · 30.09.2026

• Has Mesoblast (ASX:MSB) Cleared a Key FDA Manufacturing Hurdle for Ryoncil? (öffnet in neuem Tab)

  Kalkine Media · 30.09.2026

• Mesoblast Limited Sponsored ADR Statistics – HAN:LWB1 (öffnet in neuem Tab)

  TradingView · 29.09.2026

• ETFs Investing in Mesoblast Limited Sponsored ADR Stocks (öffnet in neuem Tab)

  TradingView · 29.09.2026

• What Sets Pro Medicus, Mesoblast and Harvey Norman Apart? (öffnet in neuem Tab)

  Kalkine Media · 29.09.2026

• Has Mesoblast (ASX:MSB) cleared a key FDA manufacturing hurdle? (öffnet in neuem Tab)

  Kalkine Media · 28.09.2026

• Could Mesoblast shares rise over 100% in 12 months? (öffnet in neuem Tab)

  The Motley Fool Australia · 27.09.2026

• MEOBF Form 4 Filings - MESOBLAST LTD SEC Form 4 (öffnet in neuem Tab)

  Stock Titan · 27.09.2026

• Mesoblast (ASX:MSB) Secures FDA Approval for New Ryoncil Potency Assay (öffnet in neuem Tab)

  Kalkine · 26.09.2026

• Mesoblast (ASX:MSB) Stock Forecast & Analyst Predictions (öffnet in neuem Tab)

  Simply Wall Street · 25.09.2026

• Mesoblast (NASDAQ: MESO) Secures FDA Approval for TIBA Potency Assay in Ryoncil Production (öffnet in neuem Tab)

  Kalkine Media · 24.09.2026

• Mesoblast wins FDA nod for new potency assay for Ryoncil (öffnet in neuem Tab)

  Seeking Alpha · 24.09.2026

• Cantor Fitzgerald reiterates Mesoblast stock rating on adult trial focus (öffnet in neuem Tab)

  Investing.com · 24.09.2026

• Mesoblast receives FDA approval for new potency assay for Ryoncil (öffnet in neuem Tab)

  Investing.com · 24.09.2026

• Mesoblast (ASX:MSB): The Developments Investors Are Watching After FDA Approval for Ryoncil Potency Assay (öffnet in neuem Tab)

  Kalkine · 24.09.2026

• Mesoblast Receives FDA Approval for New Potency Assay to Release Commercial Ryoncil Product (öffnet in neuem Tab)

  The Manila Times · 24.09.2026

• Every new batch of Mesoblast (NASDAQ: MESO)'s cell therapy will face another check after FDA approval. (öffnet in neuem Tab)

  Stock Titan · 24.09.2026

• Mesoblast Says FDA Approves New Potency Assay For Commercial Ryoncil (öffnet in neuem Tab)

  TradingView · 24.09.2026

• Mesoblast wins FDA nod for new Ryoncil potency test (öffnet in neuem Tab)

  The Motley Fool Australia · 24.09.2026

• Mesoblast Receives FDA Approval for New RYONCIL Potency Assay (öffnet in neuem Tab)

  Kalkine · 24.09.2026

• ASX Healthcare Stocks to Watch in September 2026: Sigma Healthcare (ASX:SIG), Neuren Pharmaceuticals (ASX:NEU) and Mesoblast (ASX:MSB) (öffnet in neuem Tab)

  Kalkine · 14.09.2026

• Sigma Healthcare, Neuren and Mesoblast: Financial Performance Across ASX Healthcare (öffnet in neuem Tab)

  Kalkine · 14.09.2026

• Mesoblast (ASX: MSB) — Clinical Milestones and Commercial Ambitions: Why This Biotech Is in Focus (öffnet in neuem Tab)

  Kalkine · 07.09.2026

• Mesoblast (ASX:MSB): Ryoncil Revenue and Pipeline Expansion Redefine the Commercial Story (öffnet in neuem Tab)

  Kalkine · 07.09.2026

• Mesoblast (ASX:MSB): What Could Drive Its Next Move? (öffnet in neuem Tab)

  Kalkine Media · 04.09.2026

• Mesoblast (ASX:MSB) Holds Steady — Is Ryoncil's US Launch Enough to Watch This Biotech? (öffnet in neuem Tab)

  Kalkine · 04.09.2026